3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
2
Rectal Neoplasms
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Sorafenib
8
durvalumab
4
Cisplatin
4
Gemcitabine
3
Ethiodized Oil
3
Doxorubicin
3
Chemotherapy, Adjuvant
3
Bevacizumab
3
tremelimumab
2
sodium thiosulfate
2
phosphomannopentaose sulfate
2
Watchful Waiting
2
Talaporfin
2
Radiofrequency Ablation
2
Oxaliplatin
2
Nivolumab
2
Folfox protocol
2
Celecoxib
2
Capecitabine
2
Analgesia, Patient-Controlled
2
seocalcitol
1
parecoxib
1
nolatrexed
1
linifanib
1
lenvatinib
1
ferumoxides
1
ferric carboxymaltose
1
contrast agent BR1
1
cabozantinib
1
brivanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Liver Neoplasms
×
brivanib
×
Clear all
NCT00825955
2019-10-09
BRISK PS
Bristol-Myers Squibb
Phase 3
Completed
587 enrolled